Plain-English translation of NCT06069570 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a treatment made from immune cells donated by healthy people, given as infusions into your bloodstream alongside low-dose radiation therapy. The study is designed to find the safest and most effective dose of this medication and see whether it can help control advanced cancers that have spread or are not responding to standard treatments.
Many patients with advanced lung cancer or cancer that has spread to the bones stop responding to standard chemotherapy and immunotherapy drugs. This trial exists to explore whether this new immune cell treatment might offer another option for people who have run out of other treatment choices.
You likely qualify if…
You likely don't qualify if…
You will have a 28-day screening period with blood tests, imaging scans, and a tumor biopsy to make sure you qualify. Then you will receive infusions of the immune cell medication combined with low-dose radiation therapy over 31 days. After treatment ends, you will come to clinic visits for a short-term follow-up period of 30 days, and then you will be monitored for up to 12 months total to watch for side effects and see how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States